Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2020 | Economic evaluation of population-based BRCA testing

Ranjit Manchanda • 30 Oct 2020
NCRI 2020
Breast Cancer Ovarian Cancer

Ranjit Manchanda, MD, MRCOG, PhD, Queen Mary University of London, London, UK, discusses the results of an economic evaluation of population-based BRCA1/BRCA2 mutation testing across multiple countries and health systems in breast and ovarian cancer prevention. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Ranjit Manchanda

3:19
Advances in breast and ovarian cancer screening and early detection
Ranjit Manchanda • 3 Nov 2020

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals